GSK is fined £38m for delaying generic paroxetineBMJ 2016; 352 doi: https://doi.org/10.1136/bmj.i917 (Published 12 February 2016) Cite this as: BMJ 2016;352:i917
- Clare Dyer
- The BMJ
GlaxoSmithKline, the United Kingdom’s biggest drug maker, has been fined more than £37.6m (€48m; $55m) for striking deals between 2001 and 2004 to stifle competition from generic drug manufacturers with its blockbuster antidepressant paroxetine.
The UK’s Competition and Markets Authority has fined GSK for entering “pay for delay” deals with smaller manufacturers to keep generic forms of paroxetine off the market.
In the UK 4.2 million prescriptions were issued in 2000 for Seroxat, GSK’s branded version of paroxetine, and in 2001 Seroxat was one of GSK’s best selling drugs, with sales exceeding £90m. That year Generics (UK) and …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial